The essential tremor market was valued at USD 161.08 Million in 2025 and is expected to grow at a CAGR of 6.50%, reaching USD 302.37 Million by 2035. The market growth is driven by the increasing adoption of advanced therapies such as deep brain stimulation and focused ultrasound for symptom management. Growing awareness of non-pharmacological interventions, along with rising prevalence of essential tremor in aging populations, is expected to support market expansion in the forecast period. Innovations in wearable monitoring devices further enhance treatment effectiveness and patient outcomes.
Base Year
Historical Period
Forecast Period
In March 2025, Insightec and Vattikuti Foundation partnered with AIIMS to deploy MR-guided focused ultrasound for essential tremor, enhancing treatment accessibility in India, and are expected to drive market growth during the forecast period.
One of the major market trends includes the adoption of deep brain stimulation (DBS) for essential tremor. For instance, in December 2024, Fortis Hospital, Bannerghatta Road, launched a dedicated DBS clinic to improve patient outcomes.
According to Columbia University, focused ultrasound thalamotomy provides immediate tremor relief, improving patients’ daily activities. Such advancements are expected to accelerate growth in the market during the forecast period.
Compound Annual Growth Rate
6.5%
Value in USD Million
2026-2035
*this image is indicative*
Essential tremor is among the most prevalent movement disorders, primarily affecting the hands, head, and voice, and often intensifying with movement or emotional stress. It significantly interferes with motor control and daily activities, particularly in older adults. The market was valued at USD 161.08 Million in 2025 and is witnessing steady growth driven by rising disease prevalence, continuous advancements in neurostimulation therapies, and improved diagnostic accuracy. Increasing patient awareness and expanding neurological research are further accelerating market expansion worldwide.
Rising Prevalence of Essential Tremor to Propel Market Expansion
The essential tremor (ET) market is experiencing notable growth, primarily fueled by the increasing prevalence of the disorder. According to Columbia University, ET is a common neurological condition, estimated to affect 7 to 10 million individuals in the United States alone. This rising incidence is prompting greater demand for effective treatment options, thereby stimulating market expansion. As the number of affected individuals continues to grow, the need for innovative therapies and interventions becomes more critical, positioning the ET market for sustained growth in the coming years.
The market is experiencing key trends such as minimally invasive focused ultrasound and AI-powered wearable devices.
Emphasis on Early Detection to Boost Market Demand
The market is witnessing a significant trend toward minimally invasive, incisionless therapies that improve patient outcomes and quality of life. In October 2024, United Health Services (UHS) in Upstate New York launched a focused ultrasound program to treat essential tremor, utilizing MRI-guided ultrasound energy to target the tremor source in the brain. This outpatient procedure offers rapid recovery and sustained tremor reduction, addressing the limitations of traditional medications. Adoption of such advanced therapies is expected to boost market growth over the forecast period.
Adoption of AI-Driven Wearable Devices to Boost Essential Tremor Market Value
The shift toward AI-powered, noninvasive therapeutic solutions is a significant trend shaping the market. In July 2025, Fasikl received FDA clearance for its Felix™ NeuroAI™ Wristband, marking the first and only AI-driven device designed to provide continuous, drug-free relief for adults with essential tremor. This innovation exemplifies the growing adoption of wearable bioelectronic technologies that combine artificial intelligence with personalized treatment approaches. Such advancements are expected to accelerate market expansion and enhance patient accessibility, positioning AI-enabled therapeutics as a pivotal growth driver in the coming years.
Oral Segment to Witness Significant Growth for Segmentation by Route of Administration
The market is segmented by route of administration into oral, parenteral, and others. Among these, the oral segment is expected to lead the market during the forecast period. Oral administration remains the preferred route due to its convenience, patient compliance, and the availability of effective medications such as propranolol, which serves as a first-line treatment for both essential tremor and migraine. According to an article reviewed in August 2025, propranolol extended-release capsules are widely recommended for once-daily dosing, ensuring improved adherence and therapeutic efficacy. The rising use of oral formulations and ongoing clinical recommendations supporting their dual efficacy are expected to strengthen the dominance of this segment in the coming years.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market during the forecast period, driven by a high prevalence of the disorder, advanced healthcare infrastructure, and substantial investments in research and development. Notably, in July 2025, the University of Minnesota spin-off company Fasikl received FDA clearance for its AI-powered Felix™ NeuroAI™ Wristband, a noninvasive wearable device providing all-day symptom relief for adults with essential tremor. This development highlights ongoing innovation and reinforces the United States’ market leadership.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Zydus Hospitals and Healthcare Research Private Limited is a leading healthcare provider specializing in comprehensive neurological care. The company offers advanced diagnostic and treatment services for various movement disorders, including tremor disorders, Parkinson’s disease, dystonia, and ataxia. Leveraging state-of-the-art facilities such as 3T MRI, multi-slice CT, neurophysiology labs, and neuro catheterization, Zydus delivers precise diagnosis and innovative therapies, including botulinum toxin treatments, positioning it as an active contributor in the Essential Tremor market.
Cipla Ltd., a leading global pharmaceutical company, manufactures CIPLAR tablets containing propranolol, available in 10 mg and 40 mg formulations. Propranolol, a nonselective beta-adrenergic blocker, is clinically proven to manage essential tremor by reducing tremor intensity. Through CIPLAR, Cipla actively participates in the essential tremor market, offering accessible and effective therapeutic options for patients worldwide.
AbbVie Inc., headquartered in North Chicago, Illinois, is a global biopharmaceutical company focused on innovative therapies across multiple therapeutic areas. In October 2025, the company advanced its involvement in the essential tremor market through onabotulinumtoxinA (BOTOX®), which demonstrated significant efficacy in the Phase 2 ELATE trial for upper limb essential tremor. BOTOX® showed substantial improvement in Tremor Disability Scale-Revised scores, highlighting AbbVie’s commitment to developing new treatment options for patients with this challenging neurological condition.
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company committed to providing affordable and innovative medicines across therapeutic areas. Its product BERTRED 3,5 (bortezomib), a lyophilized powder for injection, is indicated for the treatment of multiple myeloma and mantle cell lymphoma. Through products like BERTRED 3,5, Dr. Reddy’s continues to enhance its position in the neurological and movement disorder treatment segment by advancing precision-driven injectable therapies addressing conditions linked to tremor management and neurodegeneration.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Novartis AG, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Apotex Inc., and Sunovion Pharmaceuticals.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share